Spectrum Pharmaceuticals, inc. (NASDAQ:SPPI), Advaxis, inc. (OTC:ADXS), and Celgene Corporation (NASDAQ:CELG) are all in the business of fighting cancer in its various forms and 2012 looks like a good year for advancements in treatments and for bio-techs to raise capital.

All three of these companies have had significant run-ups recently and profit taking is to be expected and any subsequent dips could be just what “Value Hunters” are looking for. If you look at shares of Spectrum Pharmaceuticals, they were trading in the $9.24 range on Oct 26 and hit $15.87 on Jan 11; that’s a gain of 71.75% in less than three months. Normal profit taking off of the Jan 11 has set and shares a dipped a little to their current $14.13 range. The ten-week run-up at SIPPI was a very steady ascent with small gives and takes along the way.

On Dec 9 the Company said that the U.S. Food & Drug Administration (FDA) had granted FUSILEV Orphan Drug exclusivity for use in combination chemotherapy aimed at patients with advanced metastatic colorectal cancer. SPPI also noted FUSILEV therapeutic compositions are protected under a US Patent which expires at the end of December 2019.

At another cancer fighting biotech, Advaxis, shareholders have also seen gains in valuation. The stock was trading at $0.14 on Dec 14 and is currently trading in the $0.17 range; a gain of 21.4% in six weeks on some very choppy, but uptrend trading.

ADXS reported yesterday that it’s safety and efficacy Phase II trials for ADXS-HPV targeted for women with recurrent and/or refractory cervical cancer who have failed other therapies are returning very promising results with only 34% of trial participants experiencing non-cumulative flu-like symptoms. 

At Celgene, shares have also climbed with the stock trading at $60.24 on Nov 25 and hitting a $74.02 top of the run-up on Tuesday of this week; a gain of 22.8% in two months. There’s been a little profit taking from the top of the run and shares are currently trading in the $73.26 range.

CELG announced today it would acquire privately held Avila Therapeutics to expand Celgene’s leading role in the future treatment of hematologic cancers with Avila’s AVL-292, a highly-selective inhibitor, currently in Phase I clinical trials. 

I haven’t, don’t, and do not intend on holding any of the companies mentioned in this article.

I have been with my partner for 6 monthes and am positive that me and my partner have been clean, however recently I have developed the symptoms of Gonorrhea. how could this have happened? Why would signs not show up in the past six months? We have been exclusively sexually active with each other this entire time.

You need to get checked. It could be something else. if it's in fact gonnorhea, someone ain't tellin' the truth about exclusivity.

No they can't just develop. You said you have symptoms but you didn't say you tested positive for it. they could also be symptoms of other things. if it is gonorrhea, then someone cheated and didn't use protection.

Not to my knowledge. ask you doctor, that's the best course of action.

Respectfully,

S-42

NO…………if you, indeed, have Gonorrhea, then ONE of you hasn't been "exclusive". however, you said that you had "developed the symptoms" of Gonorrhea……..if you haven't been diagnosed by a Dr. then you may instead have something else….maybe a yeast infection or some other non STD problem. You need to get diagnosed….and if YOU haven't been unfaithful….well….someone else has.
Hope your test is negative !

Press Release Source: Reportlinker on Tuesday August 10, 2010, 10:00 am EDT

NEW YORK, Aug. 10 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:

Antipsychotic Drugs: Technologies and Global Markets

reportlinker.com/p0236244/Antipsychotic-Drugs-Technologies-and-Global-Markets.html

The total worldwide market for antipsychotic drugs is expected to reach $19.6 billion in 2010.  with continued market penetration into new diseases and price increases for currently marketed antipsychotics, this market is expected to grow to a high of $20.8 billion in 2011 and then hit a low of $14.4 billion in 2013, before resuming growth again to $14.8 billion in worldwide sales for 2014. this represents a total compound annual growth rate (CAGR) of -4.6%.

Most atypical antipsychotics will lose patent exclusivity through the study period, resulting in a compound annual growth rate (CAGR) of -3.7%. this market will be worth an estimated $18.5 billion by the end of 2010, but decrease to $14.5 billion in 2014.

Antipsychotic drug sales are expected to remain strong in long-acting injectable (depot) formulations. Long-acting injectables are forecast to record a 16.6% compound annual growth rate (CAGR) during this time period, increasing from $1.5 billion in 2009 to $3.2 billion in 2014. 

Chapter- 1: INTRODUCTION — Complimentary

STUDY GOALS AND OBJECTIVES 1

REASONS FOR DOING THIS STUDY 2

INFORMATION SOURCES 4

AUTHOR’S CREDENTIALS 4

RELATED BCC WORK CREDENTIALS 4

BCC ONLINE SERVICES 4

SUMMARY TABLE THE WORLDWIDE MARKET FOR ANTIPSYCHOTIC DRUGS, THROUGH 2014 ($, MILLIONS) 7

SUMMARY FIGURE THE WORLDWIDE MARKET FOR ANTIPSYCHOTIC DRUGS, 2010–2014 ($, MILLIONS) 7

DEFINITION OF AN ANTIPSYCHOTIC DRUG 8

HISTORY OF ANTIPSYCHOTIC DRUGS 9

TYPES OF ANTIPSYCHOTICS ON THE MARKET 10

TYPICAL ANTIPSYCHOTICS 10

Typical Antipsychotics (Continued) 11

TABLE 1 CLASSES OF TYPICAL ANTIPSYCHOTICS ON THE MARKET AND THEIR SIDE EFFECTS 12

ATYPICAL ANTIPSYCHOTICS 13

TABLE 2 CURRENTLY APPROVED ATYPICAL ANTIPSYCHOTICS ON THE MARKET 14

TABLE 2 (CONTINUED) 15

TABLE 3 FEATURES OF TYPICAL VERSUS ATYPICAL ANTIPSYCHOTICS 15

TABLE 4 COST OF SELECTED ATYPICAL AND TYPICAL ANTIPSYCHOTIC DRUGS ($) 16

RECEPTOR TARGETS OF ANTIPSYCHOTIC DRUGS 16

SIDE EFFECTS OF ANTIPSYCHOTICS 20

NEUROLOGIC SIDE EFFECTS (EXTRAPYRAMIDAL SYMPTOMS) 21

ANTICHOLINERGIC SIDE EFFECTS 22

CARDIOVASCULAR SIDE EFFECTS 22

METABOLIC SIDE EFFECTS 23

OTHER SIDE EFFECTS 24

TABLE 5 COMPARISON OF SIDE EFFECT PROFILES OF ANTIPSYCHOTICS ON THE MARKET 25

ANTIPSYCHOTICS IN CLINICAL DEVELOPMENT 25

TABLE 6 ANTIPSYCHOTICS IN CLINICAL TRIALS, ORDERED BY PHASE 26

TABLE 6 (CONTINUED) 27

TABLE 7 NUMBER OF ANTIPSYCHOTICS IN CLINICAL TRIALS, BY PHASE (NUMBER/%) 27

FIGURE 1 ANTIPSYCHOTICS IN CLINICAL TRIALS BY PRIMARY RECEPTOR TARGET 28

TABLE 8 COMPANIES WITH MORE THAN ONE ANTIPSYCHOTICS IN CLINICAL TRIALS OR ON THE MARKET* 29

Chapter-4: TECHNOLOGY OVERVIEW

TECHNOLOGY OVERVIEW 30

TABLE 9   SALES OF ATYPICAL ANTIPSYCHOTICS BY FORMULATION, THROUGH 2014 ($, MILLIONS) 31

TABLE 10 ADMINISTRATION PROFILES OF LONG-ACTING ATYPICAL ANTIPSYCHOTICS 31

Chapter-5: PATENT EVALUATION

PATENT LENGTHS AND MARKET EXCLUSIVITY 32

TABLE 11 PATENT EXPIRATION DATES FOR ANTIPSYCHOTICS ON THE MARKET OR IN PHASE III DEVELOPMENT 33

TABLE 12 SALES OF ANTIPSYCHOTICS POTENTIALLY FACING GENERIC COMPETITION BY THE END OF 2014 ($ MILLIONS) 34

Chapter-6: ANTIPSYCHOTICS ON THE MARKET AND IN DEVELOPMENT

TABLE 13 GLOBAL MARKET FOR ANTIPSYCHOTICS BY INDIVIDUAL DRUG, THROUGH 2014 ($ MILLIONS) 35

TABLE 13 (CONTINUED) 36

TABLE 14 GLOBAL MARKET FOR ANTIPSYCHOTIC DRUGS BY MECHANISM OF ACTION, THROUGH 2014 ($ MILLIONS) 37

DOPAMINERGIC ANTIPSYCHOTICS IN DEVELOPMENT 37

DOPAMINE D2/SEROTONIN 5-HT2A RECEPTOR ANTAGONISTS 37

TABLE 15 MARKET FOR D2/5-HT2A ANTAGONISTS BY REGION, THROUGH 2014 ($ MILLIONS) 38

Serdolect (Sertindole) 38

Serdolect … (Continued) 39

Solian (Amisulpride) 40

Lonasen (Blonanserin) 40

Lullan (Perospirone) 41

Saphris/Sycrest (Asenapine, ORG 5222, SCH 900274) 41

Saphris/Sycrest    (Continued) 42

Risperdal (Risperidone) 43

Risperdal Consta (Risperidone) 44

Risperdal Consta… (Continued) 45

Clozaril/Leponex (Clozapine) 46

Seroquel IR and XR (Quetiapine) 47

Seroquel IR and XR…(Continued) 48

Zyprexa (Olanzapine) 49

Zyprexa…(Continued) 50

Zyprexa Relprevv/Zypadhera (Olanzapine Pamoate) 51

Fanapt (Iloperidone) 51

Fanapt…(Continued) 52

AZ-004 (Staccato Loxapine) 53

TABLE 16 PROFILE OF AZ-004 VERSUS OTHER ANTIPSYCHOTICS FOR TREATING AGITATION 54

TABLE 17 AZ-004/STACCATO LOXAPINE STUDIES 55

Lurasidone (SM-13496) 56

TABLE 18 LURASIDONE STUDY RESULTS 57

Geodon/Zeldox (Ziprasidone) 58

Invega (Paliperidone) 59

TABLE 19 INVEGA COMPARED TO RISPERDAL 60

Invega Sustenna (Paliperidone Palmitate) 60

Zicronapine (Lu 31-130) 61

DOPAMINE D2 RECEPTOR PARTIAL AGONISTS 63

TABLE 20 MARKET FOR D2 PARTIAL AGONISTS BY REGION, THROUGH 2014 ($ MILLIONS) 64

Abilify (Aripiprazole, OPC-14597) 65

Aripiprazole Depot 66

Cariprazine (RGH-188, MP-214) 67

Cariprazine…(Continued) 68

ALKS 9070 (Long-acting Aripiprazole) 71

Bifeprunox (DU-127,090) 71

SEROTONERGIC ANTIPSYCHOTICS IN DEVELOPMENT 72

TABLE 21 SELECTED SEROTONIN RECEPTOR SUBTYPES AND ANTIPSYCHOTIC DRUGS BINDING TO THESE SITES 73

Pimavanserin (ACP-103) 74

Pimavanserin…(Continued) 75

TABLE 22 PIMAVANSERIN PHASE II ADJUNCTIVE SCHIZOPHRENIA EFFICACY RESULTS 76

5-HT6 RECEPTOR AGONISTS AND ANTAGONISTS 77

PF-5212365 (SAM-531) 78

Eplivanserin (SR46349B) 78

GLUTAMATERGIC ANTIPSYCHOTICS IN DEVELOPMENT 79

LY2140023 (Continued) 80

Glutamatergic Modulators in Preclinical Testing 82

GLYCINE TRANSPORT INHIBITORS 82

SCH 900435 (Org 25935) 82

OTHER ANTIPSYCHOTICS IN DEVELOPMENT 84

Talnetant (SB-223412) 87

Osanetant (SR-142801) 87

Licarbazepine (LIC477D) 88

Corlux (Mifepristone, RU-486, C-1073) 89

Corlux …(Continued) 90

SCH 900636 (ORG 34517) 91

Chapter-7: DISEASE APPLICATIONS

SYMPTOMS OF SCHIZOPHRENIA 94

TREATMENT OF SCHIZOPHRENIA 95

Treatment of Schizophrenia (Continued) 96

TESTS OF SCHIZOPHRENIA DRUG EFFECTIVENESS 97

Positive and Negative Syndrome Scale (PANSS) 97

Brief Psychiatric Rating Scale (BPRS) 97

Clinical Global Impression scale (CGI) 97

Scale for the Assessment of Positive Symptoms/Negative Symptoms (SAPS/SANS) 98

CATIE Phase 1 Results 99

TABLE 23 CATIE PHASE 1 ALL-CAUSE STUDY DISCONTINUATIONS 99

CATIE Phase 2 Results 100

CATIE Phase 3 Results 100

The Lancet Second-generation vs First-Generation Antipsychotics Meta-analysis 102

Young Mania Rating Scale 104

Montgomery-Asberg Depression Rating Scale 104

Hamilton Depression Rating Scale 104

MAJOR STUDIES USING ANTIPSYCHOTICS IN BIPOLAR DISORDER 105

MARKET OPPORTUNITY 106

TABLE 24 LIST OF APPROVED BIPOLAR I DISORDER USES FOR ATYPICAL ANTIPSYCHOTICS 107

MAJOR DEPRESSIVE DISORDER 108

MARKET OPPORTUNITY 109

OTHER ON- AND OFF-LABEL USES OF ANTIPSYCHOTICS 110

ANXIETY SPECTRUM DISORDERS 110

ALZHEIMER’S AND PARKINSON’S DISEASES 111

MARKET OPPORTUNITY 111

Market Opportunity (Continued) 112

Chapter-8: MAJOR COMPANIES AND MARKET SHARE

TABLE 25 FORECASTED SALES AND MARKET SHARE OF COMPANIES WITH ANTIPYSCHOTICS ON THE MARKET, 2014 ($ MILLIONS/%) 113

ACADIA PHARMACEUTICALS 114

ADDEX PHARMACEUTICALS 115

ALEXZA PHARMACEUTICALS 116

AstraZeneca – U.S. Headquarters 118

BRISTOL-MYERS SQUIBB 120

CYRENAIC PHARMACEUTICALS 121

DAINIPPON SUMITOMO PHARMA 122

FABRE-KRAMER PHARMACEUTICALS 123

JOHNSON AND JOHNSON 125

MITSUBISHI TANABE PHARMA 127

NPS PHARMACEUTICALS 130

OTSUKA PHARMACEUTICAL CO. 132

Pfizer (Continued) 133

TITAN PHARMACEUTICALS 134

VANDA PHARMACEUTICALS 135

Chapter-9: INTERNATIONAL ASPECTS AND REGULATORY ISSUES

TABLE 26 GLOBAL FORECAST FOR ANTIPSYCHOTICS MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 136

MARKET BY REGION (CONTINUED) 137

The FDA Modernization Act of 1997 138

Fast-track Status 139

Special Protocol Assessments 140

New Surveillance and Safety Requirements 140

Approvable Letters 140

Consumer Confidence 141

Other Health Care Changes 142

New Drug Approvals and Innovation 142

Drug Reimbursement and Reference Pricing 143

Relocation of R&D 144

New Drug Approvals 145

Regulatory Climate 145

Relationship Between Academia and Industry 146

Chapter-10: FUTURE DIRECTIONS

THE ROLE OF BIOMARKERS AND PHARMACOGENOMICS 147

COMBINATION THERAPIES 147

THE EFFECT OF GENERIC ANTIPSYCHOTICS ON PRICE 148

THE EFFECT OF GENERIC …(CONTINUED) 149

To order this report:

Drug and Medication Industry: Antipsychotic Drugs: Technologies and Global Markets

Drug and Medication Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Intl: +1 805-652-2626